Diligence memo · auto-generated · as of July 3, 2026
Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc. has raised $335M over 3 rounds; too few niche peers to rank its valuation yet.
Businessfiled
Aimmune Therapeutics, Inc. operates in Pharma, based in BRISBANE.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Aimmune Therapeutics, Inc. has raised $335M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $157M on 2016-11-23.
Most recent recorded round closed around 2018-11-28.
Valuation (modeled)modeled
Provath models Aimmune Therapeutics, Inc. at approximately $3.5B (range $466M–$7.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Too few comparable companies in this niche to rank the valuation fairly yet.
Financing rhythm & timingmixed
Historic cadence: a new round about every 23 months.
Last raise 7.6 yr ago; this sector typically re-raises about every 16 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.6× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 99% of Pharma peers (310 compared).
Modeled value ranks above 97% of those peers.
Peoplefiled
19 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.